The ability to identify those at increased risk based on their genotype has immediate clinical relevance, as it allows for tailored prevention or screening strategies. We have several active, ongoing programmes to develop personalised screening programme models to improve public health.
As demonstrated in the cases of breast, colorectal and prostate cancers, the combined effects of multiple risk single nucleotide polymorphisms have the potential to achieve a degree of risk discrimination that is useful for population-based prevention and screening programmes.
The decision about when to start and how often to undergo breast cancer screening is complex and should involve factors beyond gender and age.Read more
Despite the fact that most prostate cancer cases carry a good prognosis for life, prostate cancer remains the second highest cause of cancer death in men.Read more
A healthy lifestyle and exercise can reduce the risk of developing colorectal cancer, but there is also a recognised hereditary component.Read more
For early melanoma detection it is necessary to assess risk factors to identify those individuals who are at high or very high risk of developing melanoma.Read more